IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION
The paper is focused on the results of a randomised clinical trial SHIFT, which started the discussion about the choice of optimal heart rate-lowering therapy in patients with chronic heart failure (CHF). The author summarizes the benefits of adding an If channel inhibitor ivabradine to the standard...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
«FIRMA «SILICEA» LLC
2012-08-01
|
| Series: | Российский кардиологический журнал |
| Subjects: | |
| Online Access: | https://russjcardiol.elpub.ru/jour/article/view/1238 |
| _version_ | 1797857112113545216 |
|---|---|
| author | Yu. M. Lopatin |
| author_facet | Yu. M. Lopatin |
| author_sort | Yu. M. Lopatin |
| collection | DOAJ |
| description | The paper is focused on the results of a randomised clinical trial SHIFT, which started the discussion about the choice of optimal heart rate-lowering therapy in patients with chronic heart failure (CHF). The author summarizes the benefits of adding an If channel inhibitor ivabradine to the standard CHF therapy and presents the place of this medication in the modern clinical guidelines on CHF management. |
| first_indexed | 2024-04-09T20:51:23Z |
| format | Article |
| id | doaj.art-c56189bea4fb4211914345e7323cf632 |
| institution | Directory Open Access Journal |
| issn | 1560-4071 2618-7620 |
| language | Russian |
| last_indexed | 2024-04-09T20:51:23Z |
| publishDate | 2012-08-01 |
| publisher | «FIRMA «SILICEA» LLC |
| record_format | Article |
| series | Российский кардиологический журнал |
| spelling | doaj.art-c56189bea4fb4211914345e7323cf6322023-03-29T21:23:19Zrus«FIRMA «SILICEA» LLCРоссийский кардиологический журнал1560-40712618-76202012-08-01046111039IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTIONYu. M. Lopatin0Volgograd State Medical University, Volgograd Region Cardiology Centre, VolgogradThe paper is focused on the results of a randomised clinical trial SHIFT, which started the discussion about the choice of optimal heart rate-lowering therapy in patients with chronic heart failure (CHF). The author summarizes the benefits of adding an If channel inhibitor ivabradine to the standard CHF therapy and presents the place of this medication in the modern clinical guidelines on CHF management.https://russjcardiol.elpub.ru/jour/article/view/1238chronic heart failurebeta-blockersif channel inhibitor ivabradine |
| spellingShingle | Yu. M. Lopatin IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION Российский кардиологический журнал chronic heart failure beta-blockers if channel inhibitor ivabradine |
| title | IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION |
| title_full | IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION |
| title_fullStr | IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION |
| title_full_unstemmed | IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION |
| title_short | IF CHANNEL INHIBITOR IVABRADINE AND CHRONIC HEART FAILURE MANAGEMENT: FROM DISCUSSION TO ACTION |
| title_sort | if channel inhibitor ivabradine and chronic heart failure management from discussion to action |
| topic | chronic heart failure beta-blockers if channel inhibitor ivabradine |
| url | https://russjcardiol.elpub.ru/jour/article/view/1238 |
| work_keys_str_mv | AT yumlopatin ifchannelinhibitorivabradineandchronicheartfailuremanagementfromdiscussiontoaction |